NAP (CAS 211439-12-2)
Alternate Names:
Davunetide
Application:
NAP is A neuroprotective peptide
CAS Number:
211439-12-2
Molecular Weight:
824.94
Molecular Formula:
C36H60N10O12
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
NAP (NAPVSIPQ) is a synthetic peptide derived from the human protein tau. It can modulate tau phosphorylation, reduce the expression of tau proteins, and reduce the activity of enzymes involved in tau phosphorylation. It exhibits potent neuroprotective properties in cellular models of neural injury. NAP has also been found in many studies to affect microtubule assembly and/or stability in neuronal and glial cells.
NAP (CAS 211439-12-2) References
- Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. | Gozes, I. 2011. Peptides. 32: 428-31. PMID: 21050875
- NAP (davunetide) provides functional and structural neuroprotection. | Gozes, I. 2011. Curr Pharm Des. 17: 1040-4. PMID: 21524250
- Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. | Shiryaev, N., et al. 2011. Curr Pharm Des. 17: 2603-12. PMID: 21728979
- Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. | Idan-Feldman, A., et al. 2011. Neurobiol Dis. 44: 327-39. PMID: 21827858
- Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). | Gozes, I. 2011. Curr Pharm Des. 17: 3413-7. PMID: 21902667
- NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. | Quraishe, S., et al. 2013. Mol Psychiatry. 18: 834-42. PMID: 23587881
- Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). | Magen, I. and Gozes, I. 2013. Neuropeptides. 47: 489-95. PMID: 24210139
- Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death. | Scuderi, S., et al. 2014. J Mol Neurosci. 54: 395-404. PMID: 24488575
- Davunetide: Peptide therapeutic in neurological disorders. | Magen, I. and Gozes, I. 2014. Curr Med Chem. 21: 2591-8. PMID: 24533805
- NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. | Ivashko-Pachima, Y., et al. 2019. PLoS One. 14: e0213666. PMID: 30865715
- An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. | Çakici, N., et al. 2019. Psychol Med. 49: 2307-2319. PMID: 31439071
- Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial. | Dale, ML., et al. 2020. Front Neurol. 11: 606925. PMID: 33408688
- Metastatic potential of malignant tumours. | Carter, RL. 1978. Invest Cell Pathol. 1: 275-86. PMID: 391778
Inhibitor of:
Apoptosis.Substrate of:
Peptide.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NAP, 0.5 mg | sc-391778 | 0.5 mg | $62.00 | |||
NAP, 1 mg | sc-391778A | 1 mg | $106.00 |